Cinderella Broussard
Psychiatric/Mental Health · Lafayette, LANPI 1801070859
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 481 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 481 payments — averaging $28.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Alkermes, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Vanda Pharmaceuticals Inc.$1K
- Axsome Therapeutics, Inc.$876
- plus $5K from 19 others
What the payments were for
- Food & beverage$13,712100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 119 | $2,464 |
| Alkermes, Inc. | 49 | $1,908 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 49 | $1,335 |
| Otsuka America Pharmaceutical, Inc. | 34 | $1,239 |
| Vanda Pharmaceuticals Inc. | 34 | $1,116 |
| Axsome Therapeutics, Inc. | 19 | $876 |
| Teva Pharmaceuticals USA, Inc. | 23 | $852 |
| Johnson & Johnson(2 entities) | 32 | $823 |
| Neurocrine Biosciences, Inc. | 17 | $675 |
| Corium, LLC | 23 | $474 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $401 |
| E.r. Squibb & Sons, L.L.C. | 5 | $304 |
| Idorsia Pharmaceuticals US Inc | 6 | $267 |
| Tris Pharma Inc | 5 | $220 |
| Lundbeck LLC | 8 | $166 |
| Avanir Pharmaceuticals, Inc. | 7 | $147 |
| Sunovion Pharmaceuticals Inc. | 13 | $143 |
| Supernus Pharmaceuticals, Inc. | 6 | $117 |
| Ironshore Pharmaceuticals Inc. | 4 | $68 |
| Eisai Inc. | 2 | $32 |
| OWP Pharmaceuticals, Inc. | 1 | $22 |
| Collegium Pharmaceutical, Inc. | 1 | $19 |
| Pfizer | 1 | $18 |
| Indivior Inc. | 1 | $14 |
| Alfasigma USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$2,375
- ARISTADA$876
- VRAYLAR$570
- REXULTI$467
- Auvelity$357
- CAPLYTA$339
- INVEGA SUSTENNA$237
- COBENFY$228
- ARISTADA INITIO$219
- Fanapt$215
- Azstarys$123
- Austedo XR$122
- UZEDY$122
- ABILIFY MAINTENA$121
- ABILIFY ASIMTUFII$121
- QUVIVIQ$111
- INGREZZA$111
- INVEGA TRINZA$108
- INVEGA$108
- SPRAVATO$108
How this compares
$13,712 in reported general payments places this provider in the 95th percentile of 615 psychiatric/mental health providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 21 | $179,636 |
| VraylarCariprazine Hcl | 82 | $118,057 |
| RexultiBrexpiprazole | 40 | $64,433 |
| TrintellixVortioxetine Hydrobromide | 41 | $21,564 |
| AuvelityDextromethorphan Hbr/Bupropion | 13 | $13,883 |
| Oxcarbazepine | 192 | $7,313 |
| FetzimaLevomilnacipran Hcl | 11 | $5,471 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 132 | $5,340 |
| Quetiapine Fumarate | 118 | $3,066 |
| Duloxetine Hcl | 173 | $3,008 |
| Vilazodone Hcl | 45 | $2,722 |
| Buspirone Hcl | 131 | $2,267 |
| Fluvoxamine Maleate | 45 | $2,091 |
| Olanzapine OdtOlanzapine | 18 | $2,055 |
| Mirtazapine | 148 | $1,882 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $675 | $179,63621 claims |
| AbbVieVraylar, Fetzima | $2,464 | $123,52993 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,239 | $64,43340 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $401 | $21,56441 claims |
| Axsome Therapeutics, Inc.Auvelity | $876 | $13,88313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 615 psychiatric/mental health providers in Louisiana.
Other psychiatric/mental health in Lafayette
- Melissa GuilbeauLafayette$122K
- Bryant DronetteLafayette$17K
- Lore Lyndsey MoranLafayette$12K
- Danielle ThreattsLafayette$11K
- Seth WoodruffLafayette$10K
- Latonya WoodsLafayette$10K
- Laura KightLafayette$9K
- Amy LacoutureBaton Rouge$663K
- Amanda EymardHouma$617K
- Amber LittlefieldBroussard$225K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.